FDA Considering Pfizer’s Rheumatoid Arthritis Therapy Xeljanz for Ulcerative Colitis, Too

FDA Considering Pfizer’s Rheumatoid Arthritis Therapy Xeljanz for Ulcerative Colitis, Too
U.S. regulators are considering extending their approval of Pfizer’s rheumatoid arthritis therapy Xeljanz to ulcerative colitis as well. That possibility surfaced when the Food and Drug Administration accepted Pfizer’s supplemental New Drug Application for Xeljanz (tofacitinib citrate) as a treatment for adults with moderate to severe ulcerative colitis. The FDA requires a company to file a New Drug Application when it

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *